Suven Pharmaceuticals Limited
Suven Pharmaceuticals Limited (SUVENPHAR.NS) Stock Competitors & Peer Comparison
See (SUVENPHAR.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SUVENPHAR.NS | ₹1,078.00 | -0.11% | 412.4B | 98.90 | ₹10.90 | N/A |
| SUNPHARMA.NS | ₹1,815.00 | +2.04% | 4.3T | 39.75 | ₹45.53 | +0.91% |
| SUNPHARMA.BO | ₹1,815.75 | +2.07% | 4.3T | 39.74 | ₹45.50 | +0.91% |
| DIVISLAB.NS | ₹6,630.00 | +1.47% | 1.7T | 69.78 | ₹93.27 | +0.46% |
| DIVISLAB.BO | ₹6,627.00 | +1.41% | 1.7T | 69.52 | ₹93.25 | +0.46% |
| TORNTPHARM.NS | ₹4,247.80 | +0.39% | 1.4T | 62.63 | ₹66.93 | +0.83% |
| TORNTPHARM.BO | ₹4,246.65 | +0.39% | 1.4T | 66.12 | ₹63.25 | +0.83% |
| DRREDDY.NS | ₹1,285.70 | -3.32% | 1.1T | 19.54 | ₹67.82 | +1.21% |
| DRREDDY.BO | ₹1,284.05 | -3.46% | 1.1T | 19.50 | ₹67.84 | +1.21% |
| LUPIN.NS | ₹2,344.10 | +1.41% | 1.1T | 22.78 | ₹101.49 | +0.52% |
Stock Comparison
SUVENPHAR.NS vs SUNPHARMA.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUNPHARMA.NS trades at ₹1,815.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUNPHARMA.NS's P/E ratio is 39.75. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUNPHARMA.NS's competition here
SUVENPHAR.NS vs SUNPHARMA.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUNPHARMA.BO trades at ₹1,815.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUNPHARMA.BO's P/E ratio is 39.74. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUNPHARMA.BO's competition here
SUVENPHAR.NS vs DIVISLAB.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, DIVISLAB.NS has a market cap of 1.7T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while DIVISLAB.NS trades at ₹6,630.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas DIVISLAB.NS's P/E ratio is 69.78. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check DIVISLAB.NS's competition here
SUVENPHAR.NS vs DIVISLAB.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, DIVISLAB.BO has a market cap of 1.7T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while DIVISLAB.BO trades at ₹6,627.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas DIVISLAB.BO's P/E ratio is 69.52. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check DIVISLAB.BO's competition here
SUVENPHAR.NS vs TORNTPHARM.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while TORNTPHARM.NS trades at ₹4,247.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas TORNTPHARM.NS's P/E ratio is 62.63. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check TORNTPHARM.NS's competition here
SUVENPHAR.NS vs TORNTPHARM.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while TORNTPHARM.BO trades at ₹4,246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas TORNTPHARM.BO's P/E ratio is 66.12. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check TORNTPHARM.BO's competition here
SUVENPHAR.NS vs DRREDDY.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while DRREDDY.NS trades at ₹1,285.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas DRREDDY.NS's P/E ratio is 19.54. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check DRREDDY.NS's competition here
SUVENPHAR.NS vs DRREDDY.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while DRREDDY.BO trades at ₹1,284.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas DRREDDY.BO's P/E ratio is 19.50. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check DRREDDY.BO's competition here
SUVENPHAR.NS vs LUPIN.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while LUPIN.NS trades at ₹2,344.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas LUPIN.NS's P/E ratio is 22.78. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check LUPIN.NS's competition here
SUVENPHAR.NS vs LUPIN.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while LUPIN.BO trades at ₹2,344.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas LUPIN.BO's P/E ratio is 24.46. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check LUPIN.BO's competition here
SUVENPHAR.NS vs MANKIND.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, MANKIND.NS has a market cap of 926.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while MANKIND.NS trades at ₹2,248.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas MANKIND.NS's P/E ratio is 51.88. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check MANKIND.NS's competition here
SUVENPHAR.NS vs MANKIND.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, MANKIND.BO has a market cap of 924B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while MANKIND.BO trades at ₹2,251.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas MANKIND.BO's P/E ratio is 51.90. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check MANKIND.BO's competition here
SUVENPHAR.NS vs ZYDUSLIFE.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ZYDUSLIFE.NS has a market cap of 898.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ZYDUSLIFE.NS trades at ₹901.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ZYDUSLIFE.NS's P/E ratio is 18.21. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ZYDUSLIFE.NS's competition here
SUVENPHAR.NS vs ZYDUSLIFE.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ZYDUSLIFE.BO has a market cap of 897.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ZYDUSLIFE.BO trades at ₹901.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ZYDUSLIFE.BO's P/E ratio is 18.16. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ZYDUSLIFE.BO's competition here
SUVENPHAR.NS vs AUROPHARMA.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AUROPHARMA.BO has a market cap of 805B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AUROPHARMA.BO trades at ₹1,383.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AUROPHARMA.BO's P/E ratio is 23.54. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AUROPHARMA.BO's competition here
SUVENPHAR.NS vs AUROPHARMA.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AUROPHARMA.NS has a market cap of 804.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AUROPHARMA.NS trades at ₹1,385.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AUROPHARMA.NS's P/E ratio is 23.07. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AUROPHARMA.NS's competition here
SUVENPHAR.NS vs GLENMARK.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GLENMARK.NS has a market cap of 677.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GLENMARK.NS trades at ₹2,397.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GLENMARK.NS's P/E ratio is 63.73. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GLENMARK.NS's competition here
SUVENPHAR.NS vs GLENMARK.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GLENMARK.BO has a market cap of 677B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GLENMARK.BO trades at ₹2,397.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GLENMARK.BO's P/E ratio is 63.38. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GLENMARK.BO's competition here
SUVENPHAR.NS vs ALKEM.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALKEM.BO has a market cap of 649.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALKEM.BO trades at ₹5,364.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALKEM.BO's P/E ratio is 27.38. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALKEM.BO's competition here
SUVENPHAR.NS vs ALKEM.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALKEM.NS has a market cap of 649.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALKEM.NS trades at ₹5,363.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALKEM.NS's P/E ratio is 27.39. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALKEM.NS's competition here
SUVENPHAR.NS vs LAURUSLABS.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, LAURUSLABS.NS has a market cap of 597.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while LAURUSLABS.NS trades at ₹1,167.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas LAURUSLABS.NS's P/E ratio is 70.79. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check LAURUSLABS.NS's competition here
SUVENPHAR.NS vs LAURUSLABS.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, LAURUSLABS.BO has a market cap of 593.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while LAURUSLABS.BO trades at ₹1,165.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas LAURUSLABS.BO's P/E ratio is 70.41. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check LAURUSLABS.BO's competition here
SUVENPHAR.NS vs SUVENPHAR.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUVENPHAR.BO's competition here
SUVENPHAR.NS vs IPCALAB.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, IPCALAB.BO has a market cap of 388.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while IPCALAB.BO trades at ₹1,537.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas IPCALAB.BO's P/E ratio is 42.71. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check IPCALAB.BO's competition here
SUVENPHAR.NS vs IPCALAB.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, IPCALAB.NS has a market cap of 387.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while IPCALAB.NS trades at ₹1,535.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas IPCALAB.NS's P/E ratio is 42.64. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check IPCALAB.NS's competition here
SUVENPHAR.NS vs AJANTPHARM.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AJANTPHARM.NS has a market cap of 353.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AJANTPHARM.NS trades at ₹2,899.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AJANTPHARM.NS's P/E ratio is 34.81. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AJANTPHARM.NS's competition here
SUVENPHAR.NS vs AJANTPHARM.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AJANTPHARM.BO has a market cap of 352B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AJANTPHARM.BO trades at ₹2,894.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AJANTPHARM.BO's P/E ratio is 34.74. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to AJANTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AJANTPHARM.BO's competition here
SUVENPHAR.NS vs JBCHEPHARM.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, JBCHEPHARM.NS has a market cap of 329.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while JBCHEPHARM.NS trades at ₹2,074.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas JBCHEPHARM.NS's P/E ratio is 43.24. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check JBCHEPHARM.NS's competition here
SUVENPHAR.NS vs JBCHEPHARM.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, JBCHEPHARM.BO has a market cap of 328.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while JBCHEPHARM.BO trades at ₹2,084.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas JBCHEPHARM.BO's P/E ratio is 43.13. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check JBCHEPHARM.BO's competition here
SUVENPHAR.NS vs EMCURE.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, EMCURE.NS has a market cap of 321.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while EMCURE.NS trades at ₹1,748.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas EMCURE.NS's P/E ratio is 36.99. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check EMCURE.NS's competition here
SUVENPHAR.NS vs PEL.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check PEL.NS's competition here
SUVENPHAR.NS vs WOCKPHARMA.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, WOCKPHARMA.NS has a market cap of 226.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while WOCKPHARMA.NS trades at ₹1,420.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas WOCKPHARMA.NS's P/E ratio is 1090.23. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check WOCKPHARMA.NS's competition here
SUVENPHAR.NS vs WOCKPHARMA.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, WOCKPHARMA.BO has a market cap of 226.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while WOCKPHARMA.BO trades at ₹1,417.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas WOCKPHARMA.BO's P/E ratio is 1089.53. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check WOCKPHARMA.BO's competition here
SUVENPHAR.NS vs PPLPHARMA.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, PPLPHARMA.BO has a market cap of 214.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while PPLPHARMA.BO trades at ₹160.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas PPLPHARMA.BO's P/E ratio is -65.81. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check PPLPHARMA.BO's competition here
SUVENPHAR.NS vs ASTRAZEN.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ASTRAZEN.BO has a market cap of 208B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ASTRAZEN.BO trades at ₹8,093.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ASTRAZEN.BO's P/E ratio is 103.01. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ASTRAZEN.BO's competition here
SUVENPHAR.NS vs ASTRAZEN.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ASTRAZEN.NS has a market cap of 206.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ASTRAZEN.NS trades at ₹8,083.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ASTRAZEN.NS's P/E ratio is 102.17. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ASTRAZEN.NS's competition here
SUVENPHAR.NS vs NATCOPHARM.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NATCOPHARM.NS has a market cap of 195.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NATCOPHARM.NS trades at ₹1,109.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NATCOPHARM.NS's P/E ratio is 12.58. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NATCOPHARM.NS's competition here
SUVENPHAR.NS vs NATCOPHARM.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NATCOPHARM.BO has a market cap of 195.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NATCOPHARM.BO trades at ₹1,109.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NATCOPHARM.BO's P/E ratio is 12.71. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NATCOPHARM.BO's competition here
SUVENPHAR.NS vs NEULANDLAB.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NEULANDLAB.NS has a market cap of 191.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NEULANDLAB.NS trades at ₹15,996.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NEULANDLAB.NS's P/E ratio is 106.35. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NEULANDLAB.NS's competition here
SUVENPHAR.NS vs NEULANDLAB.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NEULANDLAB.BO has a market cap of 191B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NEULANDLAB.BO trades at ₹16,080.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NEULANDLAB.BO's P/E ratio is 106.25. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NEULANDLAB.BO's competition here
SUVENPHAR.NS vs COHANCE.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, COHANCE.BO has a market cap of 184.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while COHANCE.BO trades at ₹474.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas COHANCE.BO's P/E ratio is 95.63. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check COHANCE.BO's competition here
SUVENPHAR.NS vs COHANCE.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, COHANCE.NS has a market cap of 183.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while COHANCE.NS trades at ₹474.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas COHANCE.NS's P/E ratio is 94.63. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check COHANCE.NS's competition here
SUVENPHAR.NS vs ERIS.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ERIS.NS has a market cap of 183B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ERIS.NS trades at ₹1,350.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ERIS.NS's P/E ratio is 41.95. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ERIS.NS's competition here
SUVENPHAR.NS vs ERIS.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ERIS.BO has a market cap of 182.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ERIS.BO trades at ₹1,351.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ERIS.BO's P/E ratio is 41.77. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ERIS.BO's competition here
SUVENPHAR.NS vs GRANULES.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GRANULES.NS has a market cap of 173.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GRANULES.NS trades at ₹705.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GRANULES.NS's P/E ratio is 28.62. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GRANULES.NS's competition here
SUVENPHAR.NS vs GRANULES.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GRANULES.BO has a market cap of 167.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GRANULES.BO trades at ₹700.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GRANULES.BO's P/E ratio is 30.77. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GRANULES.BO's competition here
SUVENPHAR.NS vs APLLTD.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, APLLTD.BO has a market cap of 148.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while APLLTD.BO trades at ₹766.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas APLLTD.BO's P/E ratio is 23.49. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check APLLTD.BO's competition here
SUVENPHAR.NS vs APLLTD.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, APLLTD.NS has a market cap of 148B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while APLLTD.NS trades at ₹766.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas APLLTD.NS's P/E ratio is 23.49. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check APLLTD.NS's competition here
SUVENPHAR.NS vs JUBLPHARMA.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, JUBLPHARMA.NS has a market cap of 147.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while JUBLPHARMA.NS trades at ₹934.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas JUBLPHARMA.NS's P/E ratio is 34.16. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check JUBLPHARMA.NS's competition here
SUVENPHAR.NS vs JUBLPHARMA.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, JUBLPHARMA.BO has a market cap of 147B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while JUBLPHARMA.BO trades at ₹936.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas JUBLPHARMA.BO's P/E ratio is 34.12. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check JUBLPHARMA.BO's competition here
SUVENPHAR.NS vs GLS.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GLS.NS's competition here
SUVENPHAR.NS vs GLS.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GLS.BO's competition here
SUVENPHAR.NS vs CAPLIPOINT.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, CAPLIPOINT.BO has a market cap of 130B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while CAPLIPOINT.BO trades at ₹1,733.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas CAPLIPOINT.BO's P/E ratio is 21.24. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check CAPLIPOINT.BO's competition here
SUVENPHAR.NS vs CAPLIPOINT.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, CAPLIPOINT.NS has a market cap of 129.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while CAPLIPOINT.NS trades at ₹1,731.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas CAPLIPOINT.NS's P/E ratio is 21.17. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check CAPLIPOINT.NS's competition here
SUVENPHAR.NS vs ALIVUS.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALIVUS.BO has a market cap of 126B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALIVUS.BO trades at ₹1,060.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALIVUS.BO's P/E ratio is 23.23. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALIVUS.BO's competition here
SUVENPHAR.NS vs ALIVUS.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALIVUS.NS has a market cap of 125.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALIVUS.NS trades at ₹1,056.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALIVUS.NS's P/E ratio is 22.44. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALIVUS.NS's competition here
SUVENPHAR.NS vs CAPPL.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check CAPPL.BO's competition here
SUVENPHAR.NS vs STAR.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, STAR.BO has a market cap of 96.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while STAR.BO trades at ₹1,026.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas STAR.BO's P/E ratio is 18.82. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check STAR.BO's competition here
SUVENPHAR.NS vs STAR.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, STAR.NS has a market cap of 95.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while STAR.NS trades at ₹1,028.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas STAR.NS's P/E ratio is 18.70. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check STAR.NS's competition here
SUVENPHAR.NS vs VIYASH.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, VIYASH.NS has a market cap of 89.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while VIYASH.NS trades at ₹204.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas VIYASH.NS's P/E ratio is 79.10. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check VIYASH.NS's competition here
SUVENPHAR.NS vs PGHL.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, PGHL.NS has a market cap of 86.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while PGHL.NS trades at ₹5,175.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas PGHL.NS's P/E ratio is 36.53. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check PGHL.NS's competition here
SUVENPHAR.NS vs PGHL.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, PGHL.BO has a market cap of 85.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while PGHL.BO trades at ₹5,176.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas PGHL.BO's P/E ratio is 36.36. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check PGHL.BO's competition here
SUVENPHAR.NS vs AKUMS.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AKUMS.NS has a market cap of 84.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AKUMS.NS trades at ₹559.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AKUMS.NS's P/E ratio is 26.27. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AKUMS.NS's competition here
SUVENPHAR.NS vs SUDEEPPHRM.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUDEEPPHRM.NS has a market cap of 80.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUDEEPPHRM.NS trades at ₹703.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUDEEPPHRM.NS's P/E ratio is 47.68. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SUDEEPPHRM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUDEEPPHRM.NS's competition here
SUVENPHAR.NS vs SHILPAMED.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SHILPAMED.NS has a market cap of 80.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SHILPAMED.NS trades at ₹421.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SHILPAMED.NS's P/E ratio is 36.28. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SHILPAMED.NS's competition here
SUVENPHAR.NS vs AARTIPHARM.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AARTIPHARM.NS has a market cap of 67.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AARTIPHARM.NS trades at ₹790.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AARTIPHARM.NS's P/E ratio is 31.73. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AARTIPHARM.NS's competition here
SUVENPHAR.NS vs AARTIPHARM.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AARTIPHARM.BO has a market cap of 67.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AARTIPHARM.BO trades at ₹790.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AARTIPHARM.BO's P/E ratio is 31.55. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AARTIPHARM.BO's competition here
SUVENPHAR.NS vs FDC.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, FDC.BO has a market cap of 60B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while FDC.BO trades at ₹372.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas FDC.BO's P/E ratio is 27.71. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check FDC.BO's competition here
SUVENPHAR.NS vs FDC.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, FDC.NS has a market cap of 59.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while FDC.NS trades at ₹371.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas FDC.NS's P/E ratio is 27.68. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check FDC.NS's competition here
SUVENPHAR.NS vs SEQUENT.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SEQUENT.NS's competition here
SUVENPHAR.NS vs SEQUENT.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SEQUENT.BO's competition here
SUVENPHAR.NS vs SUVEN.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUVEN.BO has a market cap of 48.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUVEN.BO trades at ₹212.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUVEN.BO's P/E ratio is -17.06. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SUVEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUVEN.BO's competition here
SUVENPHAR.NS vs SUVEN.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SUVEN.NS has a market cap of 46.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SUVEN.NS trades at ₹213.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SUVEN.NS's P/E ratio is -16.99. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to SUVEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SUVEN.NS's competition here
SUVENPHAR.NS vs SPARC.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SPARC.BO has a market cap of 46.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SPARC.BO trades at ₹139.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SPARC.BO's P/E ratio is -17.32. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SPARC.BO's competition here
SUVENPHAR.NS vs SPARC.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SPARC.NS has a market cap of 46.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SPARC.NS trades at ₹139.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SPARC.NS's P/E ratio is -17.27. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SPARC.NS's competition here
SUVENPHAR.NS vs INNOVACAP.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, INNOVACAP.NS has a market cap of 42.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while INNOVACAP.NS trades at ₹842.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas INNOVACAP.NS's P/E ratio is 32.38. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check INNOVACAP.NS's competition here
SUVENPHAR.NS vs SHILPAMED.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SHILPAMED.BO has a market cap of 40.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SHILPAMED.BO trades at ₹423.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SHILPAMED.BO's P/E ratio is 36.25. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SHILPAMED.BO's competition here
SUVENPHAR.NS vs GUJTHEM.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GUJTHEM.NS has a market cap of 39.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GUJTHEM.NS trades at ₹372.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GUJTHEM.NS's P/E ratio is 82.84. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GUJTHEM.NS's competition here
SUVENPHAR.NS vs RPGLIFE.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, RPGLIFE.NS has a market cap of 38B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while RPGLIFE.NS trades at ₹2,392.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas RPGLIFE.NS's P/E ratio is 18.74. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check RPGLIFE.NS's competition here
SUVENPHAR.NS vs RPGLIFE.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, RPGLIFE.BO has a market cap of 37.8B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while RPGLIFE.BO trades at ₹2,385.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas RPGLIFE.BO's P/E ratio is 18.66. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check RPGLIFE.BO's competition here
SUVENPHAR.NS vs AARTIDRUGS.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AARTIDRUGS.NS has a market cap of 34.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AARTIDRUGS.NS trades at ₹393.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AARTIDRUGS.NS's P/E ratio is 17.04. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AARTIDRUGS.NS's competition here
SUVENPHAR.NS vs AARTIDRUGS.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, AARTIDRUGS.BO has a market cap of 34.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while AARTIDRUGS.BO trades at ₹391.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas AARTIDRUGS.BO's P/E ratio is 16.90. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check AARTIDRUGS.BO's competition here
SUVENPHAR.NS vs ORCHPHARMA.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ORCHPHARMA.BO has a market cap of 31.9B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ORCHPHARMA.BO trades at ₹637.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ORCHPHARMA.BO's P/E ratio is 166.71. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ORCHPHARMA.BO's competition here
SUVENPHAR.NS vs ORCHPHARMA.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ORCHPHARMA.NS has a market cap of 31.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ORCHPHARMA.NS trades at ₹634.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ORCHPHARMA.NS's P/E ratio is 166.12. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ORCHPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ORCHPHARMA.NS's competition here
SUVENPHAR.NS vs BLISSGVS.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, BLISSGVS.NS has a market cap of 29.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while BLISSGVS.NS trades at ₹271.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas BLISSGVS.NS's P/E ratio is 27.13. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to BLISSGVS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check BLISSGVS.NS's competition here
SUVENPHAR.NS vs BLISSGVS.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, BLISSGVS.BO has a market cap of 29.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while BLISSGVS.BO trades at ₹270.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas BLISSGVS.BO's P/E ratio is 27.16. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to BLISSGVS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check BLISSGVS.BO's competition here
SUVENPHAR.NS vs GUFICBIO.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GUFICBIO.BO has a market cap of 28.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GUFICBIO.BO trades at ₹288.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GUFICBIO.BO's P/E ratio is 57.06. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GUFICBIO.BO's competition here
SUVENPHAR.NS vs GUFICBIO.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, GUFICBIO.NS has a market cap of 28.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while GUFICBIO.NS trades at ₹287.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas GUFICBIO.NS's P/E ratio is 57.13. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check GUFICBIO.NS's competition here
SUVENPHAR.NS vs IOLCP.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, IOLCP.BO has a market cap of 27.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while IOLCP.BO trades at ₹94.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas IOLCP.BO's P/E ratio is 23.80. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check IOLCP.BO's competition here
SUVENPHAR.NS vs IOLCP.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, IOLCP.NS has a market cap of 27.6B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while IOLCP.NS trades at ₹94.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas IOLCP.NS's P/E ratio is 23.80. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check IOLCP.NS's competition here
SUVENPHAR.NS vs UNICHEMLAB.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, UNICHEMLAB.NS has a market cap of 27.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while UNICHEMLAB.NS trades at ₹386.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas UNICHEMLAB.NS's P/E ratio is 9.31. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check UNICHEMLAB.NS's competition here
SUVENPHAR.NS vs UNICHEMLAB.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, UNICHEMLAB.BO has a market cap of 27.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while UNICHEMLAB.BO trades at ₹387.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas UNICHEMLAB.BO's P/E ratio is 9.30. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check UNICHEMLAB.BO's competition here
SUVENPHAR.NS vs NOVARTIND.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NOVARTIND.BO has a market cap of 25.5B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NOVARTIND.BO trades at ₹1,019.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NOVARTIND.BO's P/E ratio is 26.22. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NOVARTIND.BO's competition here
SUVENPHAR.NS vs NOVARTIND.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, NOVARTIND.NS has a market cap of 25.4B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while NOVARTIND.NS trades at ₹1,024.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas NOVARTIND.NS's P/E ratio is 26.14. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to NOVARTIND.NS's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to NOVARTIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check NOVARTIND.NS's competition here
SUVENPHAR.NS vs SOLARA.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SOLARA.NS has a market cap of 24.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SOLARA.NS trades at ₹523.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SOLARA.NS's P/E ratio is -104.15. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SOLARA.NS's competition here
SUVENPHAR.NS vs SOLARA.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, SOLARA.BO has a market cap of 24.1B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while SOLARA.BO trades at ₹522.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas SOLARA.BO's P/E ratio is -104.28. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, SUVENPHAR.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check SOLARA.BO's competition here
SUVENPHAR.NS vs ALEMBICLTD.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, ALEMBICLTD.NS has a market cap of 23.7B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while ALEMBICLTD.NS trades at ₹92.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas ALEMBICLTD.NS's P/E ratio is 7.43. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check ALEMBICLTD.NS's competition here
SUVENPHAR.NS vs HIKAL.BO Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, HIKAL.BO has a market cap of 23.3B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while HIKAL.BO trades at ₹191.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas HIKAL.BO's P/E ratio is 236.31. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to HIKAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check HIKAL.BO's competition here
SUVENPHAR.NS vs HIKAL.NS Comparison May 2026
SUVENPHAR.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUVENPHAR.NS stands at 412.4B. In comparison, HIKAL.NS has a market cap of 23.2B. Regarding current trading prices, SUVENPHAR.NS is priced at ₹1,078.00, while HIKAL.NS trades at ₹191.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUVENPHAR.NS currently has a P/E ratio of 98.90, whereas HIKAL.NS's P/E ratio is -179.24. In terms of profitability, SUVENPHAR.NS's ROE is +0.09%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, SUVENPHAR.NS is more volatile compared to HIKAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SUVENPHAR.NS.Check HIKAL.NS's competition here